Znn3bq.jpeg
²é¿´: 1250  |  »Ø¸´: 3
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

xiaotongxyz

ľ³æ (ÕýʽдÊÖ)

[½»Á÷] ÇóÖú·­ÒëÖÐÎÄÕªÒªÒ»·Ý£¬ÖØÉͽð±Ò£¬·­ÒëµÄºÃ¿É×·¼Ó

Ô­ÎÄ£º

¹ú²úÀûÅàͪÖÎÁÆÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰ­ÁÆÐ§·ÖÎö

ÕªÒª£ºÄ¿µÄ£ºÌ½ÌÖ¹ú²úÀûÅàͪ£¨Ë¼ÀûÊæ£©ÖÎÁÆÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰ­ÁÆÐ§ºÍ°²È«ÐÔ¡£·½·¨£ºËæ»ú³éÈ¡ÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰ­30Àý£¬ÓÃ˼ÀûÊæÖÎÁÆ£¬²¢·Ö±ðÓÚÖÎÁÆÇ°¼°ÖÎÁƺóµÚ1¡¢2¡¢4¡¢8ÖÜÄ©²ÅÈ¥¼òÃ÷¾«Éñ²¡Á¿±í£¨BPRS)¡¢ÑôÐÔÖ¢×´ÒõÐÔÖ¢×´Á¿±í£¨PANSS£©¼°¸±×÷ÓÃÁ¿±í£¨TCSS£©ÆÀ¶¨ÁÙ´²ÁÆÐ§¼°²»Á¼·´Ó¦¡£½á¹û£ºBPRS×Ü·Ö¡¢PANSS×ֺܷ͸÷Ö¢×´ÆÀ·Ö¾ù½ÏÖÎÁÆÇ°ÏÔÖø½µµÍ£¬ÇÒÓÐÏÔÖø²îÒ죨P<0.01~0.05£©£¬ÓÐЧÂÊ£º90%£¬ÏÔЧÂÊ£º63%£¬³£¼û²»Á¼·´Ó¦ÊÇÌåÖØÔö¼Ó¡¢¾²×ø²»ÄÜ¡£½áÂÛ£ºË¼ÀûÊæ¶ÔÄÔѪ¹ÜËùÖª¾«ÉñÕϰ­°²È«ÓÐЧ£¬²»Á¼·´Ó¦ÉÙ£¬¾­¼ÃÊÊÓã¬ÖµµÃÁÙ´²ÍƹãʹÓá£

» ²ÂÄãϲ»¶

ÎÒ²»ÊÇÒ»¸öËæ±ãµÄÈË£¬ÎÒËæ±ãÆðÀ´²»ÊÇÈË£¬¹þ¹þ
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xiaotongxyz

ľ³æ (ÕýʽдÊÖ)

ÇóÖú½áÊø£¬ÉêÇë³·ÏúÌû×Ó£¬Í˻ؽð±Ò

ÇóÖúÒѽâ¾ö£¬ËäÓд𸴣¬µ«ÊDz»ÂúÒâ½á¹û£¬ÉêÇëÍË»ØÊ£Óà½ð±Ò
ÎÒ²»ÊÇÒ»¸öËæ±ãµÄÈË£¬ÎÒËæ±ãÆðÀ´²»ÊÇÈË£¬¹þ¹þ
4Â¥2010-05-07 11:58:31
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 4 ¸ö»Ø´ð

·Ç±ÈѰ³£

ľ³æ (СÓÐÃûÆø)

xiaotongxyz(½ð±Ò+20, ·­ÒëEPI+1):·­ÒëµÄ²»¹»×¨Òµ£¬ÓÐЩ·­Òë²»¹»×¼È·×¨Òµ 2010-04-30 01:18
Analysis of therapeutic effect of domestic Risperidone on non-psychotic disorders
resulting from cerebrovascular diseases

Abstract:
Purpose: to probe into therapeutic effect and security of domestic Risperidone on non-psychotic disorders resulting from cerebrovascular diseases.
Approach: to randomly draw 30 cases with non-psychotic disorders resulting from cerebrovascular diseases, treat them with Risperidone and then assess clinical curative effects and undesirable reactions with BPRS, PANSS and TCSS at the end of the first, second, fourth and eighth week before and after treatment. Result: aggregate score of BPRS and PANSS and each symptom score are considerablely much lower than that before treatment with significant variation
(P<0.01~0.05). The effective rate is 90% and developing rate is 63%. Common undesirable reactions are gain in weight and loss of sitting still.
Conclusion: Risperidone is secure and effective with a few undesirable reactions and deserves promotion and application because of its economically affordable and applicable trait on the treatment of non-psychotic disorders resulting from cerebrovascular diseases.
ѧ»áÈ¡Éᣡ
2Â¥2010-04-29 21:53:09
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

pharmjackie

ľ³æ (ÕýʽдÊÖ)

xiaotongxyz(½ð±Ò+30):ǰ°ë²¿·Ö·­ÒëºÜºÃ£¬ºó°ë²¿·Ö²»¹»ÀíÏ룬רҵÐÔÔÙǿЩ¾ÍºÃÁË 2010-04-30 01:22
efficacy of Risperidone on brain vascular diseases caused psychonosema

Abstract  Object: to evaluate the efficacy and safety of Risperidone on brain vascular diseases caused psychonosema. Method: A total of 30 patients with psychonosema was randomly selected to treat with Risperidone, and clinical efficacy and adverse effect was recorded using BPRS, PANSS, and TCSS before treatment and at the end of 1, 2, 4, 8 weeks after treatment. Results: BPRS scores, PANSS scores and symptom scores decreased significantly compared to that of pre-treatment (P<0.01~0.05). Effective percentage is 90% while the obvious effective rate is 63%. Common adverse effects include: Weight gain, akathisia. Conclusion: Risperidone¡¯s effectiveness, safety and minor adverse effect makes itself worthy of clinical use.
3Â¥2010-04-29 22:10:21
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ±¾¿ÆÄÏ·½Ò½¿Æ´óѧ Ò»Ö¾Ô¸985 ҩѧѧ˶284·Ö Çóµ÷¼Á +4 ÈõË®ÌýÎÄ 2026-04-09 4/200 2026-04-10 22:01 by doctff
[¿¼ÑÐ] 284Çóµ÷¼Á +19 èó@@ 2026-04-06 21/1050 2026-04-10 21:12 by zhouxiaoyu
[¿¼ÑÐ] ¼ª´ó¼ÆËã»ú¼¼Êõ331·Ö£¬Ó¢ÓïÁù¼¶£¬Çóµ÷¼Á +3 ·å·å021116 2026-04-09 3/150 2026-04-10 20:01 by chemisry
[¿¼ÑÐ] ±¾¿ÆÎ÷¹¤´ó 324Çóµ÷¼Á +4 wysyjs25 2026-04-10 4/200 2026-04-10 20:00 by À´¿´Á÷ÐÇÓê10
[¿¼ÑÐ] 266Çóµ÷¼Á +29 ÑôÑôÍÛÈû 2026-04-07 29/1450 2026-04-10 16:20 by ¸ßά´º
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +11 Ò»ÑùYWY 2026-04-05 11/550 2026-04-10 09:32 by ÖÓÖÞ2011
[¿¼ÑÐ] 277Çóµ÷¼Á +19 Äß½¨Éè 2026-04-06 19/950 2026-04-10 09:24 by guosr9609
[¿¼ÑÐ] ±¾¿ÆÎ÷¹¤´ó 0856 324Çóµ÷¼Á +10 wysyjs25 2026-04-09 11/550 2026-04-10 08:37 by 5268321
[¿¼ÑÐ] Çóµ÷¼Á +8 ³Ô¿Ú±ù¼¤Áè 2026-04-07 8/400 2026-04-09 08:03 by 5268321
[¿¼ÑÐ] 264Çóµ÷¼Á +11 ÂóС¶£µ± 2026-04-07 11/550 2026-04-08 16:05 by Ò»Ö»ºÃ¹û×Ó?
[¿¼ÑÐ] 265Çóµ÷¼Á +19 Сľ³æ085600 2026-04-06 21/1050 2026-04-08 10:38 by ÄæË®³Ë·ç
[¿¼ÑÐ] 11408 325·Ö +3 jgtxuxgkx 2026-04-07 3/150 2026-04-07 23:10 by lbsjt
[¿¼ÑÐ] 312Çóµ÷¼Á +18 gtw1 2026-04-06 20/1000 2026-04-07 18:16 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 22408 µ÷¼Á²ÄÁÏ +7 ÎÒ½Ðez 2026-04-06 8/400 2026-04-07 17:12 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 304Çóµ÷¼Á +4 luoye0105 2026-04-05 4/200 2026-04-06 21:05 by ľ×Ó¾ý1218
[¿¼ÑÐ] »úеר˶274Çóµ÷¼Á£¬²»ÌôרҵѧУ +6 ·º·º2333 2026-04-05 8/400 2026-04-06 18:06 by ·º·º2333
[¿¼ÑÐ] 315Çóµ÷¼Á +5 £¦123456789 2026-04-05 5/250 2026-04-05 19:55 by nepu_uu
[¿¼ÑÐ] µ÷¼Á +3 Àî¹ã»ð 2026-04-05 3/150 2026-04-05 18:57 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 313Çóµ÷¼Á +5 º£ÈÕº£ÈÕ 2026-04-04 7/350 2026-04-05 13:58 by imissbao
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£© +8 ÏàÐűػá¹ââÍòÕ 2026-04-05 10/500 2026-04-05 12:19 by Hdyxbekcb
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û